GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) Business Wire Nawigacja wpisu News: The Latest Clinical Trial Updates from CRISPR Medicine News – CRISPR Medicine News GSK buys liver drug from Boston Pharmaceuticals for up to $2 billion – The Boston Globe
